News

IMS Health study: Up to 15% of healthcare system costs avoidable and effective patient activation by multiple stakeholders is key to driving improvement.

Find out where each presidential candidate stands on key issues related to pharmaceutical costs.

Humana and UCS study shows prevalence of ageism in film and the power of embracing a healthy mindset for healthy aging

Migration to high-deductible plans partly responsible, according to Kaiser Family Foundation survey.

FDA’s pace of biosimilar approvals is picking up, as it approved two major drugs for rheumatoid arthritis and other inflammatory diseases in the past month.

FDA recently approved an expanded use for Invokamet (Janssen): Invokamet XR, an extended-release combination drug to treat type 2 diabetes. The original Invokamet was approved by FDA in 2014.

To identify the top managed care pharmacy challenges and what your peers are doing about them, Managed Healthcare Executive, in partnership with Access Market Intelligence and the National Institute of Collaborative Healthcare, conducted its first-ever pharmacy survey during the second quarter of 2016.

When is retail right? Consider these four benefits that will impact the bottom line.

HHS finalized ClinicalTrial.gov rules encourage healthcare improvement and public benefit by increasing transparency and accountability across the industry.

Why today’s models will always be interim ones-andhow the consumerization of healthcare will drive change.

Expert offers specific actions for managed care execs to take

In today’s increasingly consumer-driven environment, personalization is not only expected, but a demanded part of the user experience.

FDA approved once-daily Yosprala (Aralez), a fixed-dose combination of aspirin, an anti-platelet agent and omeprazole, a proton pump inhibitor (PPI), for patients who require aspirin for secondary prevention of cardiovascular (CV) and cerebrovascular events and who are at risk of developing aspirin-associated gastric ulcers.Here are the top 5 facts to know about Yosprala.

Even though an FDA panel recommended against approving a new drug to treat Duchenne muscular dystrophy in April, the agency granted accelerated approval to eteplirsen injection (Exondys 51, Sarepta Therapeutics) in mid-September.

Industry leaders share who they call when they need advice.

A new study shows that many adults with depression don’t receive treatment, whereas others receive treatments that do not match their level of illness severity.

Two fertility experts detail the pros and cons of a fertility benefit plan.

Nationwide class action suit spurs new coverage decision for hepatitis C medications.

A new database helps payers understand which genetic tests are available, which genes they test for, and which tests would be appropriate to use to inform patient management.

Patient engagement is central to improving health outcomes and reducing the cost of care. Yet, there continues to be a huge disconnect between patients, payers, and physicians.

Here are five ways to use big data and predictive analytics to get insights about members and create a personalized member experience.

A new study highlights why vaccination costs should be a top consideration when evaluating benefit offerings.

Here’s how you can take advantage of this breathing room.

Market forces are converging, giving momentum to provider-sponsored health plans.

Study shows that an integrated pharmacy approach with community mental health centers produces higher adherence rates and lower overall healthcare costs.

As external pressures such as government regulations continue to mount and alter the approach to deal making in the healthcare sector, there are five things health services executives should watch.

Where do the capabilities of healthcare technology end and the need for the human hand begin to deliver top value for managed care executives?

Several recent studies explore how weight loss surgery impacts diabetes patient care.

Early planning to craft a comprehensive real-world evidence generation strategy can help support the real-world safety and effectiveness of biosimilars.

FDA’s approval of a new biosimilar-the third FDA-approved biosimilar-stands to save the US healthcare system millions of dollars.